Johnson & Johnson (JNJ) stock has risen 3.6% over the past week, fallen 4.0% over the past month, and surged 61.8% over the past year. Wall Street’s analysts are moderately bullish, forecasting further gains with a 12‑month price target of $264.75, suggesting upside from the last closing price of $230.42.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Analyst David Risinger of Leerink Partners has upgraded JNJ to Buy, setting a fresh price target of $265.00. This implies meaningful upside and reflects a view that strong new drug momentum will drive faster revenue growth and potential stock outperformance.
Risinger boosted his valuation by raising the target price from $252, now assuming stronger long‑term revenue and earnings growth. He highlights that near‑term earnings estimates are mostly unchanged, but he now expects total company revenue to grow at a 7.2% five‑year CAGR from 2026 to 2031.
A key part of his thesis is the launch of Icotyde, an oral IL‑23 therapy for psoriasis with best‑in‑class efficacy among oral agents, along with promising data in ulcerative colitis. He also points to Inlexzo for bladder cancer, Rybrevant’s subcutaneous FASPRO formulation, and Tremfya’s rapid growth in inflammatory bowel disease as important growth drivers.
Risinger, ranked 87 out of 12,188 analysts with a 63.21% success rate and 30.30% average return per rating, significantly raised Icotyde sales projections above consensus through 2032. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.